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Abstract
Introduction: The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer’s
disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibitors
(ChEI).
Methods: In an open, three-year, nonrandomized, prospective, multicenter study, 843 patients were treated with
donepezil, rivastigmine, or galantamine in a routine clinical setting. At baseline and every six months, patients were
assessed using several rating scales, including the Mini-Mental State Examination (MMSE) and the Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-cog) and the dose of ChEI was recorded. Sociodemographic
and clinical characteristics were investigated. The relationships of these predictors with longitudinal cognitive ability
were analyzed using mixed-effects models.
Results: Slower long-term cognitive decline was associated with a higher cognitive ability at baseline or a lower
level of education. The improvement in cognitive response after six months of ChEI therapy and a more positive
longitudinal outcome were related to a higher mean dose of ChEI, nonsteroidal anti-inflammatory drug (NSAID)/
acetylsalicylic acid usage, male gender, older age, and absence of the apolipoprotein E (APOE) ε4 allele. More
severe cognitive impairment at baseline also predicted an improved response to ChEI treatment after six months.
The type of ChEI agent did not influence the short-term response or the long-term outcome.
Conclusions: In this three-year AD study performed in a routine clinical practice, the response to ChEI treatment
and longitudinal cognitive outcome were better in males, older individuals, non-carriers of the APOE ε4 allele,
patients treated with NSAIDs/acetylsalicylic acid, and those receiving a higher dose of ChEI, regardless of the drug
agent.
Introduction
Alzheimer’s disease (AD) is the most prevalent cause of
dementia among the elderly, accounting for 50% to 60%
of cases [1]. This progressive neurodegenerative disease
affects approximately 24 million individuals worldwide,
with one new case detected every seven seconds [2]. AD
patients exhibit the following symptoms: decline in
executive functions, memory impairment, visuospatial
and language difficulties, and behavioral disturbances
[3].
The loss of cholinergic transmission is assumed as one
of the causes of the cognitive deterioration detected in
patients with AD [4]. Based on this cholinergic
hypothesis, several acetylcholinesterase inhibitors
(ChEIs) have been introduced as treatments for AD.
The ChEIs available currently (that is, donepezil, rivas-
tigmine, and galantamine) yielded modest improvements
in cognition and global performance compared with pla-
cebo treatment in subjects with varying degrees of AD
severity. The benefits of this treatment regarding activ-
ities of daily living (ADL) and behavior were also
observed [5,6].
However, not every patient benefits from ChEI treat-
ment. The heterogeneity in cognitive outcome and
response to treatment emphasize the importance of
identifying patients who respond positively to the treat-
ment, to enhance the drug’s efficacy and its cost benefits
in AD [7].
No prospective head-to-head studies of ChEI therapy
in AD longer than two years have been published. Two
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two-year trial of donepezil vs rivastigmine [8] and a
one-year comparison of donepezil and galantamine [9].
The three drug agents were compared in several natura-
listic six- to nine-month studies from the Italian
Chronos project [10-12] and in one study from Spain
[13]. Regarding cognition, all but one study found no
differences between the drugs. A 12-week open-label
trial showed that donepezil was superior to galantamine
[14]. Conflicting results concerning ADL have been
described [8,10,14].
The longitudinal course of AD is complex and several
sociodemographic and clinical factors, such as younger
age or higher education [15,16], being a carrier of the
apolipoprotein E (APOE) ε4 allele [17], or moderate-to-
severe level of dementia [15,18] have been suggested to
increase the rate of cognitive decline in untreated
patients. Other studies showed that these variables had
no effect on disease progression: age [16], education
[19], presence of the APOE ε4 allele [20], or level of
dementia [21]. An improved response to ChEI treatment
was observed in patients who were more cognitively
impaired [7,22]. Inconsistent results were found regard-
ing gender [23,24] and age [10,25]. The divergent results
of these studies imply that the influence of these factors
needs further investigation. Advanced multivariate
methods can provide a clearer pattern of the complex
impact of predictors.
In this study, we used mixed-effects models (linear
and nonlinear) to achieve a higher resolution in the ana-
lysis of the long-term association between potential pre-
dictive characteristics, including a comparison of the
three ChEI agents, on the cognitive outcome of AD
patients in a routine clinical setting.
The aims of this study were: 1) to identify the sociode-
mographic and clinical factors that influence the longi-
tudinal cognitive outcome and response to ChEI
treatment, and 2) to study the impact of different ChEI
agents and dosages.
Materials and methods
Study and subjects
The Swedish Alzheimer Treatment Study (SATS) was
started to investigate the long-term efficacy of ChEI
treatment in naturalistic AD patients in clinical practice.
SATS is a three-year, open-label, observational, nonran-
domized, multicenter study that was described in detail
previously [26]. Its purpose is the evaluation of cogni-
tion, global performance, and ADL every six months.
The subjects were prospectively recruited from 14 mem-
ory clinics located in different areas of Sweden. Most
participants are in the mild-to-moderate stages of the
disease and the SATS is still ongoing. All subjects exhi-
biting a baseline Mini-Mental State Examination
(MMSE) [27] score ranging from 10 to 26 and for
whom at least three measurements were available per
individual (to model nonlinearity in the trajectories bet-
ter) [28,29] were included in this study. A total of 843
patients (donepezil, n = 456; rivastigmine, n = 183; and
galantamine, n = 204) who were enrolled until the end
of December 2005 fulfilled these criteria, thus having
the opportunity to complete the full three-year SATS
program.
Outpatients aged 40 years and older who met the cri-
teria for the clinical diagnosis of dementia, as defined by
the Diagnostic and Statistical Manual of Mental Disor-
ders,4
th edition (DSM-IV) [30], and for possible or
probable AD, according to the criteria of the National
Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and related Dis-
orders Association (NINCDS-ADRDA) [31], were con-
sidered for inclusion. All patients were diagnosed by
physicians specialized in dementia disorders. Moreover,
the selected patients had to live at home at the time of
diagnosis, have a responsible caregiver, and be assessable
with the MMSE at the start of the ChEI treatment
(baseline). After the baseline assessments, patients were
prescribed a ChEI treatment according to the approved
product labeling and paid for their own medication, as
in a routine clinical practice. The choice of drug and
dosage for the individual patient was left entirely up to
the physician’s discretion and professional judgment.
Medications other than anti-dementia drugs were
allowed and documented during the study. Reasons for
study withdrawal were recorded and presented for this
cohort of patients. Nursing-home placement was not a
reason for dropout if the patient was able to continue to
visit the clinic.
All patients and/or caregivers provided informed con-
sent to participate in the study, which was conducted
according to the provisions of the Helsinki Declaration
and was approved by the Ethics Committee of Lund
University, Sweden.
Outcome measures
Cognitive ability was assessed using the MMSE, with
scores ranging from 0 to 30 (a lower score indicating
more impaired cognition), and the Alzheimer’sD i s e a s e
Assessment Scale-cognitive subscale (ADAS-cog) [32],
with a total range of 0 to 70 (a higher score indicating a
more impaired cognition).
The Instrumental Activity of Daily Living (IADL) scale
[33] consists of eight different items: ability to use the
telephone, shopping, food preparation, housekeeping,
laundry, mode of transportation, responsibility for own
medications, and handling of finances. Each item was
scored from 1 (no impairment) to 3 to 5 (severe impair-
ment), which yielded a total range of 8 to 31 points. A
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was performed to avoid gender-dependent activities
affecting the result [34]. The Physical Self-Maintenance
Scale (PSMS) [33] consists of six different items: toilet,
feeding, dressing, grooming, physical ambulation, and
bathing. Each item was scored from 1 (no impairment)
to 5 (severe impairment), which allowed a total range of
6 to 30 points. Trained dementia nurses obtained the
A D Le v a l u a t i o nf r o ma ni n t e r v i e ww i t ht h ec a r e g i v e r .
To facilitate the comparison of rates in MMSE, ADAS-
cog, IADL, and PSMS scores, changes in score were
converted to positive values, which were indicative of
improvement, and negative values, which were indicative
of decline.
Statistical analyses
The IBM SPSS statistics software (version 18.0; SPSS
Inc., Chicago, IL, USA) was used to perform the statisti-
cal analyses. The level of significance was defined as P <
0.05 if not otherwise specified. Observed-case analyses
were performed to avoid overestimation of the treat-
ment effect by imputing higher, previous outcome
scores in a long-term study of a progressively deteriorat-
ing disease.
One-way analysis of variance (ANOVA) with Bonfer-
roni correction was used to compare the differences
among the means obtained for the three independent
groups, a t test was performed to analyze two indepen-
dent groups, and a c
2 test was computed to analyze
categorical variables.
Estimates of effect sizes were computed using Cohen’s
d (d = difference in group means/error SDwithin).
Cohen’s d was calculated as the difference between pre-
dicted means from the final mixed-effects model for a
given pair of groups divided by the estimated within-
group error standard deviation in the model.
Mixed models
Mixed, linear and nonlinear, fixed and random coeffi-
cient regression models [35] using “subject” as a hier-
archical variable (that is, to allow correlation within
subjects) were analyzed. The mixed models method
also takes into account variations in the number of fol-
low-up assessments available for the participants and
unequal time intervals between the collected data
points, which are common statistical limitations
observed in longitudinal studies. The non-completers
contributed information during the time of participa-
tion; thus, we considered the trajectories of all patients.
Collinearity analyses of the variables included in the
models showed no sign of multicollinearity, that is, the
undesirable situation where one independent variable
is a linear function of other independent variables.
Model assumptions were checked using residual
analyses.
Time was defined as the exact number of months
between the baseline and each visit, thus using all data
points at the correct time intervals. To adjust for baseline
differences, the initial cognitive scores for each patient and
their interaction with linear and quadratic terms for
months in the study (to enable a nonlinear rate of decline
in the models) were included as fixed effects, that is, Time
in months (or Time in months
2) × MMSE (or ADAS-cog)
baseline score. Thus, the dependent variables were the
cognitive scores assigned at the second and subsequent
assessments for each patient; that is, the models do not
intend to predict the scores at the start of ChEI treatment.
The random terms in the models were an intercept and
time in months, with an unstructured covariance matrix.
Several sociodemographic and clinical background vari-
ables were also included as fixed effects. The predictors
investigated were classical risk factors, such as age at first
assessment (in years), the clinician’s estimate of age at
onset (in years), gender, years of education, carrier of the
APOE ε4 allele, solitary living, functional ability, and num-
ber of medications at baseline. In addition, concomitant
medications (antihypertensive/cardiac therapy, anti-dia-
betics, lipid-lowering agents, estrogens, nonsteroidal anti-
inflammatory drugs (NSAIDs)/acetylsalicylic acid, antide-
pressants, antipsychotics, and anxiolytics/sedatives/hypno-
tics) were included. The impact of ChEI treatment was
analyzed using the different drug agents and dosages.
Finally, some biologically plausible interactions with cogni-
tive severity at the start of treatment or with time in the
study were included in the models, that is, gender, educa-
tion, age, and functional ability at baseline. The terms
“gender with carrier of APOE ε4 allele” and “type of ChEI
with dose” were also included.
The ChEI agents were coded as a set of dummy vari-
ables. The dose could vary during the treatment period
for an individual patient and between patients. There-
fore, the mean dose used during the entire follow-up
period was calculated for each patient. Furthermore, to
obtain a similar metric of percent maximum dosage for
the three ChEIs, the mean dose was divided by the max-
imum recommended dose for each drug, that is, 10 mg
for donepezil, 12 mg for rivastigmine, and 24 mg for
galantamine. The change of dosage between the assess-
ments was also calculated using the percentage of maxi-
mum dose. Nonsignificant variables (P >0 . 0 5 )w e r e
removed in a backward stepwise elimination manner.
The hierarchical principle was observed in these ana-
lyses; terms that appeared in interactions were not con-
sidered for elimination.
Results
Baseline characteristics
The demographic and clinical characteristics of the 843
patients, who were divided into groups corresponding to
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tigmine (n = 183, 22%), and galantamine (n = 204, 24%),
are displayed in Table 1. The rivastigmine cohort exhib-
ited a significantly smaller proportion of individuals liv-
ing alone (22%) compared with the donepezil (38%) and
galantamine (35%) groups (P < 0.001).
Lipid-lowering agents were only used by 6% of the
donepezil-treated subjects, whereas 16% of the patients
in the other two cohorts were treated with this type of
medication (P < 0.001). The usage of anti-diabetics and
antipsychotics differed between the donepezil and the
galantamine cohort: 4% vs 8% (P = 0.048) and 6% vs 2%
(P = 0.015), respectively.
The donepezil-treated subjects had a higher mean age
of onset of AD (F(2, 836) = 3.80, P = 0.023), were older
(F(2, 840) = 5.69, P = 0.004), and exhibited a more
impaired basic ADL ability (F(2, 825) = 4.40, P =0 . 0 1 3 )
at the start of the ChEI treatment compared with the
galantamine cohort. A higher level of education was
found among the individuals treated with galantamine
(F(2, 838) = 8.00, P < 0.001), whereas lower cognitive
ability, as assessed using ADAS-cog scores (F(2, 824) =
10.32, P <0 . 0 0 1 )( b u tn o tu s i n gt h eM M S E ) ,a n dm o r e
impaired instrumental ADL ability at baseline (F(2, 825)
= 14.18, P < 0.001) were detected for the donepezil
cohort compared with the other patients.
The three ChEI groups did not differ in gender, car-
rier status of APOE ε4 allele, completion rate after three
years, medication use (antihypertensive/cardiac therapy,
estrogens, NSAIDs/acetylsalicylic acid, antidepressants,
and anxiolytics/sedatives/hypnotics), estimated duration
of AD, MMSE baseline score, number of medications at
baseline, or number of visits per subject.
No difference in MMSE or ADAS-cog scores at the
start of ChEI treatment was detected regarding gender,
presence of the APOE ε4 allele (no/yes), or usage of
NSAID/acetylsalicylic acid therapy (no/yes). Male
patients had significantly more years of education com-
pared with females (mean ± SD, 9.7 ± 2.8 vs 9.2 ± 2.3
years; t(839) = 3.09; P = 0.003). A higher level of educa-
tion was also observed for individuals carrying the
APOE ε4 allele compared with non-carriers (9.6 ± 2.6 vs
9.1 ± 2.2 years; t(825) = -2.68; P = 0.005). No significant
difference regarding mean years of education was found
Table 1 Demographic and clinical characteristics
Donepezil Rivastigmine Galantamine Total subjects P-value
Variable N = 456/54% N = 183/22% N = 204/24% N = 843
Female gender 295/65% 106/58% 133/65% 534/63% 0.229
APOE ε4 carrier, (n = 829) 303/68% 119/66% 143/72% 565/68% 0.456
Solitary living at baseline 173/38%
a 40/22%
b 72/35%
a 285/34% < 0.001
Completion rate after three years 190/42% 85/46% 93/46% 368/44% 0.447
Antihypertensives/Cardiac therapy 177/39% 83/45% 70/35% 330/39% 0.096
Anti-diabetics 16/4%
a 8/4%
a, b 16/8%
b 40/5% 0.048
Lipid-lowering agents 29/6%
a 30/16%
b 33/16%
b 92/11% < 0.001
Estrogens 38/8% 13/7% 8/4% 59/7% 0.124
NSAIDs/Acetylsalicylic acid 127/28% 65/36% 61/30% 253/30% 0.160
Antidepressants 114/25% 42/23% 53/26% 209/25% 0.754
Antipsychotics 26/6%
a 4/2%
a, b 3/2%
b 33/4% 0.015
Anxiolytics/Sedatives/Hypnotics 63/14% 26/14% 24/12% 113/13% 0.750
Variable Mean ± standard deviation (SD) P-value
Estimated age at onset, years 72.6 ± 6.8
a 71.6 ± 7.9
a, b 70.9 ± 8.4
b 71.9 ± 7.4 0.023
Estimated AD duration, years 3.1 ± 2.2 3.1 ± 2.5 2.9 ± 1.6 3.0 ± 2.1 0.380
Age at first assessment, years 75.7 ± 6.4
a 74.6 ± 7.5
a, b 73.7 ± 8.1
b 75.0 ± 7.1 0.004
Education, years 9.3 ± 2.4
a 9.0 ± 2.3
a 10.0 ± 2.8
b 9.4 ± 2.5 < 0.001
MMSE score at baseline 21.2 ± 3.8 21.6 ± 3.8 21.8 ± 3.6 21.4 ± 3.8 0.070
ADAS-cog score (0 to 70) at baseline 21.8 ± 8.8
a 19.6 ± 8.9
b 18.7 ± 8.7
b 20.6 ± 8.9 < 0.001
IADL score at baseline 16.7 ± 5.5
a 15.3 ± 5.1
b 14.4 ± 5.3
b 15.9 ± 5.4 < 0.001
PSMS score at baseline 7.6 ± 2.3
a 7.4 ± 1.8
a, b 7.1 ± 2.0
b 7.4 ± 2.1 0.013
Number of medications at baseline 2.8 ± 2.3 3.0 ± 2.6 2.8 ± 2.5 2.8 ± 2.4 0.448
Mean dose of ChEI during the entire follow-up period, mg/day 7.1 ± 1.8 6.5 ± 2.1 16.1 ± 3.4
Follow up-visits per subject 5.9 ± 1.8 6.1 ± 1.7 6.1 ± 1.7 6.0 ± 1.8 0.380
a, b Results from post hoc tests (Bonferroni correction) are indicated by superscript letters (two groups with the same letter do not differ significantly within that
variable).
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, Apolipoprotein E; ChEI, cholinesterase inhibitors; IADL, Instrumental
Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NSAID, Nonsteroidal anti-inflammatory drugs; PSMS, Physical Self-Maintenance Scale.
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therapy and those who did not. Carriers of the APOE ε4
allele were significantly younger at the start of ChEI
treatment compared with non-carriers (74.2 ± 7.2 vs
76.4 ± 6.7 years; t(827) = 4.08; P < 0.001). Patients
receiving NSAID/acetylsalicylic acid therapy were older
than those not using this medication (77.4 ± 5.5 vs 73.9
± 7.5 years; t(839) = -6.76; P < 0.001). No significant age
difference was detected between genders.
To describe and compare the cognitive ability at base-
line among patients with various ages and years of edu-
cation, patients were divided into three subgroups
according to age (≤ 70, 71 to 80, and > 80 years) and
education (≤ 9, 10 to 12, and > 12 years). The oldest age
group (> 80 years) was significantly more impaired than
the other groups regarding its ADAS cog score of 22.4
± 9.0 compared with 19.9 ± 9.5 for the ≤ 70 years group
and 20.2 ± 8.5 for the 71 to 80 years group (F(2, 824) =
4.47, P = 0.012). Using the MMSE scale, there were no
differences in baseline scores among the age groups.
The group with the lowest level of education (≤ 9 years)
had a significantly lower cognitive ability at baseline
(MMSE, 21.1 ± 3.8; ADAS-cog, 21.2 ± 8.8) compared
with the highest educated group (> 12 years) (MMSE,
22.9 ± 3.3; (F(2, 838) = 11.43; P < 0.001; and ADAS-cog,
17.6 ± 8.5; (F(2, 822) = 7.87; P < 0.001).
Long-term outcomes
The MMSE mean difference from the baseline score
(95% confidence interval (CI)) was -0.6 (-0.8 to -0.3)
after one year of ChEI treatment, -2.3 (-2.7 to -1.9) after
two years, and -3.2 (-3.7 to -2.7) after three years. The
ADAS-cog mean difference from the baseline score
(95% CI) was -1.8 (-2.3 to -1.3), -4.8 (-5.6 to -4.0), and
-7.3 (-8.5 to -6.1), at one, two, and three years after the
start of treatment, respectively. No differences were
detected among the three ChEI agents.
ChEI dose
During the study, an increasing number of patients
received higher doses of ChEI. After one year, the mean
± SD doses of donepezil, rivastigmine, and galantamine
were 7.7 ± 2.5, 7.7 ± 2.9, and 18.8 ± 4.5 mg, respec-
t i v e l y .A f t e rt w oy e a r s ,t h e yw e r e8 . 3±2 . 4 ,8 . 2±2 . 9 ,
and 19.4 ± 4.7 mg, respectively. Finally, after three years,
the doses were 8.4 ± 2.4, 8.3 ± 2.7, and 20.0 ± 4.7 mg,
respectively.
Dropout analyses
Overall, 56% of the patients who had at least three
assessments did not complete the three-year study. The
reasons for dropout from the study were: admission to
nursing home (13%, n = 110), initiation of concomitant
memantine therapy (8%, n = 66), poor effect/deteriora-
tion (6%, n = 48), death (5%, n = 44), withdrawal of
informed consent (5%, n = 39), compliance problems
(4%, n = 37), side effects (4%, n = 35), switching to
another study (3%, n = 24), switching to another ChEI
agent (2%, n = 18), somatic disease unrelated to ChEI
treatment (2%, n = 17), and other reasons (4%, n = 35).
Table 2 shows that the completers exhibited signifi-
cantly better cognitive and functional abilities at the
start of the ChEI treatment compared with the non-
completers (P < 0.001) and received a higher mean dose
of ChEI during the study (P < 0.001). The other vari-
ables of interest in this study, such as gender, presence
of the APOE ε4 allele, age at baseline, years of educa-
tion, and usage of NSAIDs/acetylsalicylic acid, did not
differ between the completers and those who discontin-
ued the study.
In the multivariate mixed models, a better six-month
response to ChEI therapy was observed for the comple-
ters using both MMSE and ADAS-cog scores as out-
come variables (P = 0.001). However, the subsequent
long-term rate of cognitive decline was not different
between the completers and the non-completers.
Adjustment for “dropout” (no/yes) as an additional inde-
pendent variable in the models did not alter the out-
come of the other significant predictor variables.
Factors that affected the outcome
Mixed-effects (fixed and random, linear and nonlinear)
models were performed (4,136 observation points) to
Table 2 A comparison of the completer and non-
completer groups
Completers Non-
completers
P-value
Variable N = 368/44% N = 475/56%
Female gender 64% 62% 0.614
APOE ε4 carrier 67% 69% 0.652
Estimated age at onset,
years
a
71.8 ± 7.4 72.1 ± 7.5 0.513
Age at first assessment,
years
a
74.9 ± 7.1 75.0 ± 7.2 0.744
Education, years
a 9.4 ± 2.5 9.4 ± 2.5 0.978
MMSE score at baseline
a 22.3 ± 3.4 20.7 ± 3.9 < 0.001
ADAS-cog score (0 to 70) at
baseline
a
18.2 ± 8.3 22.4 ± 8.9 < 0.001
IADL score at baseline
a 14.5 ± 5.3 16.9 ± 5.2 < 0.001
PSMS score at baseline
a 7.0 ± 1.7 7.8 ± 2.3 < 0.001
Number of medications at
baseline
a
2.8 ± 2.5 2.8 ± 2.3 0.827
NSAIDs/Acetylsalicylic acid 29% 31% 0.649
ChEI-dose
b 70% 63% < 0.001
a Mean ± standard deviation
bMean percentage of the maximum recommended dose, that is, 10 mg
donepezil, 12 mg rivastigmine and 24 mg galantamine.
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive
subscale; APOE, Apolipoprotein E; IADL, Instrumental Activities of Daily Living
scale; MMSE, Mini-Mental State Examination; NSAID, Nonsteroidal anti-
inflammatory drugs; PSMS, Physical Self-Maintenance Scale.
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affected the long-term MMSE and ADAS-cog outcomes.
The models, significant predictors, and unstandardized
b coefficients with 95% CI are presented in Table 3; the
predicted mean scores with 95% CI are presented in
Table 4. Estimates of effect sizes using Cohen’s d for
significant predictors in the final mixed models are pre-
sented in Table 5. Slower deterioration in cognitive abil-
ity was observed for patients with less cognitive
impairment at baseline. Non-carriers of the APOE ε4
allele (ADAS-cog only) and patients receiving NSAID/
acetylsalicylic acid therapy or a higher dose of ChEI
(regardless of drug agent) exhibited a greater response
to ChEI therapy after six months, with Cohen’s d values
ranging from 0.22 to 0.50, indicating small to medium
effect sizes. The interaction effects of cognitive severity
and age at baseline, time in months from the start of
treatment, gender, and years of education showed that
these variables cannot be interpreted separately. Male
patients exhibited a greater response to ChEI treatment
after six months compared with females, as measured
using the MMSE scale, although the effect size was
small (0.19) (Figure 1a). In addition, an interaction effect
between gender and ADAS-cog score at baseline
demonstrated that this difference and the magnitude of
effects were more pronounced in subjects who were
more cognitively impaired (Figure 1b). As an example,
male individuals with a baseline ADAS-cog score of 40
responded, on average, 3.1 points better than females,
and males with a baseline ADAS-cog score of 20
Table 3 Factors affecting the long-term outcome with MMSE or ADAS-cog score as dependent variables
MMSE ADAS-cog
Percentage of variance accounted for, all fixed terms 53.7%, P < 0.001 57.8%, P < 0.001
Significant predictors in final mixed models b 95% CI (b) P-value b 95% CI (b) P-value
Fixed terms
Intercept -25.766 -36.047, -15.484 < 0.001 -8.756 -19.030, 1.518 0.095
Time in months from baseline -0.507 -0.605, -0.409 < 0.001 -0.211 -0.381, -0.040 0.016
MMSE (ADAS-cog) baseline score 2.666 2.074, 3.259 < 0.001 1.604 1.157, 2.051 < 0.001
MMSE (ADAS-cog) baseline score
2 -0.018 -0.028, -0.008 < 0.001 ns
Time in months × MMSE (ADAS-cog) baseline score 0.023 0.019, 0.027 < 0.001 0.016 0.011, 0.021 < 0.001
Time in months
2 × MMSE (ADAS-cog) baseline score -0.0001 -0.0001, -0.0001 < 0.001 0.0001 0.00004, 0.0002 0.004
Background variables:
Gender (male = 0, female = 1) -0.395 -0.718, -0.072 0.017 -1.290 -3.262, 0.681 0.199
MMSE (ADAS-cog) baseline score × Gender ns 0.110 0.020, 0.199 0.016
APOE ε4 carrier (no = 0, yes = 1) ns 1.072 0.239, 1.906 0.012
NSAIDs/Acetylsalicylic acid (no = 0, yes = 1) 0.440 0.094, 0.785 0.013 -1.037 -1.890, -0.184 0.017
Education, years 0.085 0.017, 0.153 0.014 -0.147 -0.339, 0.044 0.131
Time in months × Education, years -0.013 -0.019, -0.007 < 0.001 0.018 0.003, 0.033 0.016
Age at first assessment, years 0.361 0.237, 0.485 < 0.001 0.168 0.036, 0.300 0.013
MMSE (ADAS-cog) baseline score × Age -0.017 -0.023, -0.011 < 0.001 -0.012 -0.018, -0.006 < 0.001
IADL score at baseline -0.090 -0.124, -0.056 < 0.001 0.256 0.170, 0.343 < 0.001
ChEI-dose
a 0.010 0.001, 0.018 0.024 -0.040 -0.062, -0.019 < 0.001
Random terms (variance)
Intercept 2.613 2.166, 3.153 < 0.001 13.887 10.274, 18.770 < 0.001
Time in months 0.027 0.023, 0.032 < 0.001 0.131 0.108, 0.158 < 0.001
Solitary living, concomitant medications with the exception of NSAIDs/Acetylsalicylic acid, age at onset, basic ADL ability, change of dosage and the variable
comparing the ChEI agents were not significant.
b values were unstandardized and are expressed per one unit increase for continuous variables and for the condition present in dichotomous variables.
aMean percentage of the maximum recommended dose, that is, 10 mg donepezil, 12 mg rivastigmine and 24 mg galantamine.
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, Apolipoprotein E; ChEI, Cholinesterase inhibitors; CI, Confidence
interval; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NSAID, Nonsteroidal anti-inflammatory drugs; ns, not significant.
Table 4 Predicted mean scores from the mixed models
(95% confidence interval)
MMSE ADAS-cog
Months in study
6 21.6 (21.3, 21.8) 22.1 (21.4, 22.7)
12 20.6 (20.3, 20.8) 24.0 (23.3, 24.8)
18 19.4 (19.2, 19.7) 26.2 (25.4, 27.0)
24 18.2 (17.9, 18.5) 28.6 (27.8, 29.5)
30 16.8 (16.4, 17.2) 31.2 (30.2, 32.2)
36 15.3 (14.9, 15.7) 34.0 (32.9, 35.0)
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive
subscale; MMSE, Mini-Mental State Examination.
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Page 6 of 13responded an additional 0.9 points better compared with
females.
Older individuals exhibited a better response to treat-
ment compared with younger subjects, if they had
MMSE scores < 22 at baseline (Figure 2a) and through
all levels of ADAS-cog score (Figure 2b). The interaction
Cognitive ability × Age at the start of treatment exhib-
ited a greater age difference and larger effect sizes (0.53
to 1.55) for patients with more cognitive severity. For
example, 85-year-old individuals with a baseline MMSE
score of 15 responded on average 2.2 points better than
65-year-old individuals, and 85-year-old individuals with
a baseline ADAS-cog score of 40 responded an addi-
tional 6.2 points better compared with 65-year-old indi-
viduals after six months of ChEI treatment. Moreover,
there was an interaction effect between years of educa-
tion and time in the study. Differential dropout over
time did not cause this effect, as no difference regarding
mean years of education was detected for patients with
different numbers of assessments (F(5, 835) = 1.56; P =
0.168). A higher level of education implied increased
cognitive impairment over time, with a magnitude of
effects of 0.38 to 1.10 after three years. As an example,
a subject with 15 years of education exhibited on aver-
age an additional 2.2 points of MMSE and 3.0 points of
ADAS-cog deterioration after three years compared with
an individual with nine years of education.
If not otherwise specified, the arbitrary examples of
patients presented in the figures were based on an aver-
age male that was aged 75 years, was a carrier of the
APOE ε4 allele, did not receive NSAID/acetylsalicylic
acid therapy, had nine years of education, exhibited an
IADL score of 16, and received 65% of the maximum
recommended dose of ChEI.
The background variables solitary living, concomitant
medications (with the exception of NSAIDs), age at
onset, basic ADL ability, type of ChEI agent, change of
dosage and the interaction effects, Gender × Carrier of
APOE ε4 allele, and Type of ChEI × Dose were not sig-
nificant when included in the mixed models. The per-
centages of variance accounted for in the dependent
variable, regarding all fixed predictors, were 53.7% for
MMSE and 57.8% for ADAS-cog, which implies a good
fit of the models (P < 0.001).
Discussion
Using mixed models, we found that a higher mean dose
of ChEI, male gender, older age, NSAID/acetylsalicylic
acid therapy, and absence of the APOE ε4a l l e l ew e r e
predictors of a better short-term ChEI-treatment
Table 5 Cohen’s d effect size estimates for significant predictors in final mixed models
MMSE ADAS-cog
a
Time in months from start of ChEI treatment 6 12 36 6 12 36
Pairs of groups
Males vs females
b 0.19 0.19 0.19 ADAS-cog score 40 0.77 0.77 0.77
30 0.50 0.50 0.50
20 0.23 0.23 0.23
Age, 85 vs 65 years
b MMSE score 15 1.07 1.07 1.07 ADAS-cog score 40 1.55 1.55 1.55
20 0.24 0.24 0.24 30 0.95 0.95 0.95
25 -0.58 -0.58 -0.58 20 0.36 0.36 0.36
Age, 85 vs 75 years
b MMSE score 15 0.53 0.53 0.53 ADAS-cog score 40 0.78 0.78 0.78
20 0.12 0.12 0.12 30 0.48 0.48 0.48
25 -0.29 -0.29 -0.29 20 0.18 0.18 0.18
Age, 75 vs 65 years
b MMSE score 15 0.53 0.53 0.53 ADAS-cog score 40 0.78 0.78 0.78
20 0.12 0.12 0.12 30 0.48 0.48 0.48
25 -0.29 -0.29 -0.29 20 0.18 0.18 0.18
Education, 9 vs 15 years -0.03 0.20 1.10 -0.06 0.10 0.75
Education, 12 vs 15 years -0.01 0.10 0.55 -0.03 0.05 0.38
Education, 9 vs 12 years -0.01 0.10 0.55 -0.03 0.05 0.38
APOE ε4, non-carrier vs carrier ns ns ns 0.27 0.27 0.27
NSAIDs/Acetylsalicylic acid therapy, yes vs no 0.22 0.22 0.22 0.25 0.25 0.25
ChEI-dose, 100% vs 50%
c 0.24 0.24 0.24 0.50 0.50 0.50
a To facilitate comparisons of effect sizes, the plus/minus sign is reversed for ADAS-cog.
bDue to the interaction effects ADAS-cog baseline score × Gender, MMSE baseline score × Age and ADAS-cog baseline score × Age, effect sizes are presented for
MMSE scores of 15, 20 and 25 and for ADAS-cog scores of 20, 30 and 40, which are used as arbitrary examples.
cMean percentage of the maximum recommended dose, that is, 10 mg donepezil, 12 mg rivastigmine and 24 mg galantamine.
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, Apolipoprotein E; ChEI, Cholinesterase inhibitors; MMSE, Mini-Mental
State Examination; NSAID, Nonsteroidal anti-inflammatory drugs; ns, not significant.
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Page 7 of 13Figure 1 Cognitive outcome and gender. a) MMSE, prediction of outcome for different baseline scores divided by gender Three-year mean
outcomes with 95% confidence intervals predicted by the mixed models for patients with different Mini-Mental State Examination (MMSE)
scores (15, 20, and 25 were used as arbitrary examples), at the start of ChEI treatment and according to gender. Males demonstrated a better six-
month treatment response compared with females (P = 0.010). The calculated outcomes were based on a 75-year-old patient who did not
receive NSAID/acetylsalicylic acid treatment, had nine years of education, exhibited an IADL baseline score of 16, and received 65% of the
maximum recommended dose of ChEI. b) ADAS-cog, prediction of outcome for different baseline scores divided by gender. Three-year mean
outcomes with 95% confidence intervals predicted by the models for patients with different Alzheimer’s Disease Assessment Scale-cognitive
subscale (ADAS-cog) scores (20, 30, and 40 were used as arbitrary examples), at the start of treatment and according to gender. Male subjects
showed a better response to treatment compared with females. An interaction effect of ADAS-cog baseline score × Gender was detected (P =
0.015), that is, the difference between genders increased with lower baseline scores. The calculated outcomes were based on a 75-year-old
patient who was an APOE ε4 carrier, did not receive NSAID/acetylsalicylic acid treatment, had nine years of education, exhibited an IADL
baseline score of 16, and received 65% of the maximum recommended dose of ChEI.
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Page 8 of 13Figure 2 Cognitive outcome and age. a) MMSE, prediction of outcome for different baseline scores and ages. Three-year mean outcomes with
95% confidence intervals predicted by the mixed models for patients with different Mini-Mental State Examination (MMSE) baseline scores (15,
20, and 25) and ages (65, 75, and 85 years), used as arbitrary examples. Older subjects with a baseline MMSE score < 22 exhibited a better six-
month treatment response compared with younger patients (P < 0.001). In addition, the interaction MMSE score × Age at the start of ChEI
treatment showed a more pronounced age difference at lower baseline scores (P < 0.001). The calculated outcomes were based on a male
patient who did not receive NSAID/acetylsalicylic acid treatment, had nine years of education, exhibited an IADL baseline score of 16, and
received 65% of the maximum recommended dose of ChEI. b) ADAS-cog, prediction of outcome for different baseline scores and ages. Three-
year mean outcomes with 95% confidence intervals predicted by the models for patients with different Alzheimer’s Disease Assessment Scale-
cognitive subscale (ADAS-cog) baseline scores (20, 30, and 40) and ages (65, 75, and 85 years), used as arbitrary examples. Older individuals
exhibited a better response to treatment compared with younger subjects (P = 0.043). The interaction ADAS-cog score × Age at the start of
treatment showed a greater age difference at lower baseline levels (P < 0.001). The calculated outcomes were based on a male patient who was
an APOE ε4 carrier, did not receive NSAID/acetylsalicylic acid treatment, had nine years of education, exhibited an IADL baseline score of 16, and
received 65% of the maximum recommended dose of ChEI.
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Page 9 of 13response and long-term outcome. The type of ChEI did
not influence the results. The patients that were more
severely impaired cognitively exhibited a better response
to ChEI therapy, but declined faster subsequently. Indi-
viduals with a lower level of education showed a slower
cognitive decline. These findings were similar for both
the MMSE and ADAS-cog scales; however, ADAS-cog
is more sensitive in detecting effects, which gives cred-
ibility to the results. For example, the graded effects of
baseline cognitive ability with gender or with age were
observed more clearly using the ADAS-cog scale and
had larger effect sizes.
Our SATS cohort reflects the alteration of patient
characteristics and treatment of AD over more than one
decade. During the years that ChEI treatment has been
available, the patient population has evolved to become
younger, better educated, and exhibit less disease sever-
ity at baseline. The prescription of lipid-lowering agents
has become more common, whereas antipsychotics have
been less used, as more patients seek care and treatment
at an earlier stage of AD. In this study, these differences
were observed between the donepezil cohort enrolled
earlier and the galantamine subjects included later. Simi-
lar changes were described in other long-term studies
[36] and show the need for using advanced multivariate
methods, such as mixed models, to compensate ade-
quately for differences and effects of interactions or
time between the treatment cohorts.
The rate of disease progression varies among AD
patients; however, the knowledge on prognostic factors
is limited [37]. In the present study, a faster deteriora-
tion in cognition was observed for the patients that
were more severely impaired after their initial response
to treatment. A more rapid decline in ADL performance
in individuals with lower cognitive ability was also
described in a recent study from our group [34]. More-
over, in this study, a better cognitive response to treat-
ment was observed among males, which was in
agreement with the multivariate results obtained in a
three-month study of tacrine and galantamine [23]. A
lower percentage of males was also described among the
rapid progressors in a longitudinal study of progression
rate [38]. Inconsistently, a review of sex influences on
ChEI treatment in AD found that a clear relation was
not established between gender and response to therapy.
The possible sex differences reported in that review
were small and exhibited large individual variation; thus,
this subject requires further investigation. The morpho-
logical brain differences between genders or sex hor-
mones are theories that could explain this dissimilar
response to treatment [39].
Older age was a predictor of a better treatment
response in the current study, whereas the subsequent
rate of cognitive deterioration was not related to age.
However, an interaction effect between age and cogni-
tive severity was identified. The oldest patients (> 80
years) in this study were more cognitively impaired at
baseline and exhibited a marked positive response to
ChEI therapy; however, severity, and not age, predicted
a faster long-term progression. In contrast, the younger-
age group (< 65 years) showed greater improvement in
a three-month donepezil study that used a univariate
analysis [25]. However, the patients had a somewhat
lower mean cognitive ability compared with that of our
cohort, and the analysis did not adjust for that factor,
which could influence the outcome (as discussed above).
A recent meta-analysis model of AD progression
reported the absence of a significant impact of age; how-
ever, the distribution of the mean age in the model was
narrow [40]. Other studies found a faster rate of cogni-
tive decline in younger individuals [15,37]. It is reason-
able to assume that AD progresses more rapidly when
the disease is detected at younger ages, as hereditary
and more aggressive variants of the disease may have a
greater influence on the outcome [37].
In the present study, the individuals with the highest
education (> 12 years) were less cognitively impaired at
their baseline assessment, which is consistent with the
patient characteristics described in a recent paper on
progression rate [38]. A higher level of education was
associated with faster cognitive deterioration in this
study, as well as in several other reports [15,16,41], and
with faster ADL decline, as reported in a previous study
from our group [34]. Bennett et al. [42] suggested that
the association between senile plaques and the level of
cognitive function varies according to years of educa-
t i o n ,a si ta p p e a r e dt h a tm o r ee d u c a t i o np r o v i d e ss o m e
form of cognitive reserve. Furthermore, in accordance
with this “brain-reserve hypothesis” [41], subjects with
more years of education are expected to have higher
cognitive ability during adulthood, thus requiring a rela-
tively greater burden of pathology when dementia is
clinically evident [42]. Nevertheless, some studies found
inconsistent results or no association between the level
of education and the rate of cognitive decline. Years of
education or age had no significant effects in a multi-
variate comparison of ChEI- and memantine-treated
patients, performed by Atri et al.[ 2 9 ] ;h o w e v e r ,t h e
measures of dispersion in that cohort were small com-
pared with those of our study. In contrast to the results
of the current study, the group of slow pre-progressors
observed by Doody et al. [38] had a higher level of edu-
cation, but this variable was not a significant predictor
of longer-term ADAS-cog outcome. The high value of
mean years of education (approximately 13 to 14 years)
reported in these American cohorts [29,38] suggests a
more narrow selection of patients compared with the
sample included in the SATS (mean, 9.4 years of
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Page 10 of 13education). In Sweden, the health system is publicly
funded and the income or insurance coverage of indivi-
duals is rarely an issue when seeking care [43].
In line with the results of this study regarding APOE
genotype, Martins et al. [44] used a mixed model with
nonlinear terms and observed that the presence of at
least one APOE ε4 allele may precipitate the rate of cog-
nitive decline. Conflicting evidence regarding whether
the ε4 allele influences disease progression was found in
other studies that used linear models [17,20]. Nonlinear
models proved to fit the data better compared with lin-
ear models in Martins’ s t u d y[ 4 4 ] ;m o r e o v e r ,t h em i x e d
models method also takes the individual variability into
account, which increases the variance explained to a lar-
ger extent. Unlike some studies of response to tacrine,
which exhibited inconsistent associations between
APOE genotype and gender, an open-label trial of done-
pezil demonstrated an absence of significant differences
between the responses of ε4-carriers and non-carriers
[24].
Interestingly, divergent results concerning the relation-
ship between AD progression and NSAID treatment
have been discussed and this potential connection
remains unresolved. In epidemiological studies, NSAIDs
exhibited neuroprotective effects, suggesting a greater
reduction in risk of AD with longer use of these drugs
[45]. The Rotterdam study showed that a reduction in
risk was only observed after the first two years of cumu-
lative NSAID therapy [46] and the US Veterans study
reported a marked decrease in the odds ratio for AD
after four years of NSAID usage [47]. In contrast to our
naturalistic study, the two randomized trials reported
most recently, an 18-month [48] and a 12-month [49]
study, found no beneficial effect of NSAID treatment vs
placebo on cognitive response in AD populations. It is
possible that these trials did not include a follow-up
time that was sufficient for a protective effect to emerge
compared with the longer perspective of the SATS.
Longitudinal naturalistic studies with more detailed
information regarding the specific NSAIDs used, dosing,
and so on, are needed to investigate further this poten-
tially important finding. Knowledge of the factors that
cause differences in outcome is essential for a better
understanding of AD and its rate of progression.
Our study, as well as most previous publications com-
paring the three ChEI agents, showed no difference in
effect on cognitive outcome among the drugs [11,12].
However, higher doses of ChEIs were associated with a
more positive long-term cognitive outcome in the pre-
sent study, which is in agreement with the results of a
meta-analysis of randomized trials, as the latter showed
that larger ChEI doses were related to a larger effect
[50]. Theoretically, if we assumed that the patients
received 100% of the maximum recommended ChEI
dose, instead of the average 65% observed in the SATS,
our model would estimate a six-month mean response
to therapy of 4.0 ADAS-cog points, instead of 2.6 points.
Treatment with a higher dose of ChEI was also related
to significant delays in nursing-home placement [51,52].
These results suggest the importance of using adequate
ChEI doses in AD therapy.
The advantages of the SATS are the well-structured
and prospective assessments of a large number of ChEI-
treated AD patients in routine clinical settings. Recog-
nized scales are administered in a uniform manner
across all centers. The scheduled six-month visits and
access to a responsible contact nurse for each subject
represent security, continuity, and good quality of care.
The three-year completion rate of 44% obtained for the
present cohort is high compared with other AD exten-
sion or naturalistic studies. Most prior publications
report 20% to 39% completers after three years [53-55].
The high dropout rate in long-term AD studies may
contribute to greater mean cognitive scores for the
patients remaining in the study, assuming that they ben-
efit more from ChEI therapy. Our results showed that
the completers received a higher mean dose of ChEI
during the study, suggesting a better tolerance of the
treatment. In the models, the outcomes of the non-com-
pleters were also included during their time of participa-
tion. Other than the lower cognitive and functional
abilities at baseline observed for the non-completers,
which the multivariate mixed models took into account,
those patients were similar to the completers regarding
the other characteristics. The reasons for dropout in
long-term AD studies are complex and may vary consid-
erably. For example, dropout caused by nursing-home
placement might depend not only on the worsening of
AD, but also on somatic diseases or changes in the
health status of the caregiver.
The SATS is an open-label, nonrandomized study that
might have variations between the treatment cohorts,
which were not addressed by the model variables. The
fact that placebo-controlled designs are not permitted
(because of ethical concerns) is a limitation of AD ther-
apy studies longer than six months; therefore, no con-
trol group was enrolled in the SATS. The presence of
behavioral, psychotic, and extrapyramidal symptoms was
not recorded in this study; these are factors that have
been reported as affecting the rate of decline [28]. To
compensate somewhat for this limitation, the use of psy-
chiatric medications was included in the models; how-
ever, these variables exhibited no significant effect on
outcome.
The ability to predict and distinguish overall outcomes
would provide clinicians and the social services with
better tools to estimate the disease prognosis, manage
the patients, and plan for the future. It is important to
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Page 11 of 13recognize and treat patients with a better probability of
response or a more aggressive course of AD as early as
possible [56]. Knowledge and awareness of critical char-
acteristics that may influence the response to, and out-
come of, pharmaceutical trials are important. To
improve the management of patients and enhance the
efficacy of ChEI therapy and its cost benefits, it is essen-
tial to understand factors that influence response to
treatment and longitudinal outcome in a routine clinical
setting. For example, the patients that had more cogni-
tive impairment in our study exhibited a better response
to therapy, stressing the importance of not excluding
this group from treatment opportunities.
Conclusions
In conclusion, this study showed that male gender,
older age, absence of the APOE ε4 allele, and NSAID/
acetylsalicylic acid treatment or a higher mean dose of
ChEI were predictors of better response to ChEI ther-
apy and of a more favorable longitudinal outcome.
Lower cognitive ability at baseline was a predictor of
improved response to ChEI treatment. The long-term
outcome was better for patients with a higher cognitive
level at the start of therapy or for less-educated indivi-
duals. The demographic and clinical composition of
the AD cohort under study may be one of the explana-
tions for the heterogeneity of results observed in dif-
ferent studies. Future studies are warranted to
investigate differences in response to treatment and
longitudinal outcome based on various patient charac-
teristics. Long-term protective effects, such as the pos-
sible impact of NSAIDs or other protective treatments,
may take years to develop. The knowledge gained from
naturalistic ChEI treatment studies will continue to be
important.
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